CRISPR-based diagnostics as a specificity layer for the early detection of pancreatic cancer.
Although pre-analytical limitations remain to be fully characterized, integrating CRISPR into the diagnostic workflow may contribute to a rapid, cost-effective, and highly specific framework for the early detection of PDAC.